期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Standard Versus Extended Pancreaticoduodenectomy in Treating Adenocarcinoma of the Head of the Pancreas 被引量:1
1
作者 Jun Gong Gang Mai +5 位作者 Zhen-jiang Zheng Guang-ming Xiang Wei-ming Hu Bo-le Tian Zhao-da Zhang Xu-bao Liu 《Chinese Medical Sciences Journal》 CAS CSCD 2013年第2期107-112,共6页
Objectives To compare the postoperative complications and survival of standard pancreatoduodenectomy (SPD) and extended pancreatoduodenectomy (EPD) in patients with resectable adenocarcinoma of the head of the pan... Objectives To compare the postoperative complications and survival of standard pancreatoduodenectomy (SPD) and extended pancreatoduodenectomy (EPD) in patients with resectable adenocarcinoma of the head of the pancreas. Methods Between January 1994 and December 2011, 165 patients with biopsy-proven adenocardnoma of the pancreatic head were treated in West China Hospital, among whom 93 underwent SPD and 72 had EPD. Complications and survival after the surgery were analyzed retrospectively. Results The median operation time of the EPD group was longer compared with the SPD group (375 minutes vs. 310 minutes, P〈O.O1), the volume of blood transfusion was larger (700 mL vs. 400 mL, P〈0.05), while the median hospital stay (13.5 days vs. 12 days, P = 0.79) and the total complication rates were comparable (34.7% vs. 32.4%, P=0.93). The total recurrence rates of the SPD and EPD groups were not significantly different (52.7% vs. 43.1%, P=0,83). No significant differences were found between the SPD and EPD groups in 1-year (81.7% vs. 86.1%), 3-year (38.7% vs. 43.1%), 5-year (16.7% vs. 19.4%), and median survivals (19.8 months vs. 23.2 months, P= 0.52). Conclusion The postoperative complications and survival donot differ significantly between SPD and EPD. 展开更多
关键词 PANCREAS cancer PANCREATICODUODENECTOMY standard resection extendedresection
下载PDF
T2Flair切除范围和术后辅助化疗疗程对脑胶质母细胞瘤患者预后的影响
2
作者 鲁明 周辉 +6 位作者 邓星海 卢建侃 贺小军 林德留 顾有明 赖名耀 杨明明 《中华神经医学杂志》 CSCD 北大核心 2017年第6期591-594,共4页
探讨MRIT2Flair切除范围和术后辅助化疗疗程对人脑胶质母细胞瘤(GBM)患者预后的影响。方法广东三九脑科医院神经外五科自2012年4月至2016年8月在唤醒麻醉、神经导航和神经电生理监测等技术下采用肿瘤切除术治疗GBM患者17例,现回顾性... 探讨MRIT2Flair切除范围和术后辅助化疗疗程对人脑胶质母细胞瘤(GBM)患者预后的影响。方法广东三九脑科医院神经外五科自2012年4月至2016年8月在唤醒麻醉、神经导航和神经电生理监测等技术下采用肿瘤切除术治疗GBM患者17例,现回顾性分析患者的临床资料和疗效,探讨MRIT2Flair切除范围和术后辅助化疗疗程对人脑GBM患者预后的影响。结果17例患者T1增强病灶均全部切除。患者中位生存时间20个月。T2Flair切除体积比0~10%、10%~25%、大于25%组患者术后中位生存时间分别为19、22、24个月,3组患者的生存率比较差异无统计学意义(P〉0.05)。术后辅助化疗疗程〈6次、≥6次组患者的中位生存时间分别为19、33个月,术后辅助化疗疗程〈6次组患者的生存率低于术后辅助化疗疗程≥6次组,差异有统计学意义(P〈0.05)。结论T1增强病灶全切除时,T2Flair切除范围对GBM患者的预后无明显影响:而术后辅助化疗疗程≥6次的GBM患者的预后较好。 展开更多
关键词 胶质母细胞瘤 T2Flair 扩大切除 化疗 疗程
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部